Supernus Pharmaceuticals Profit Margin 2011-2024 | SUPN

Current and historical gross margin, operating margin and net profit margin for Supernus Pharmaceuticals (SUPN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Supernus Pharmaceuticals net profit margin as of September 30, 2024 is 9.16%.
Supernus Pharmaceuticals Annual Profit Margins
Supernus Pharmaceuticals Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.997B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $18.693B 6.13
Dr Reddy's Laboratories (RDY) India $12.070B 23.10
BridgeBio Pharma (BBIO) United States $5.195B 0.00
Bausch Health Cos (BHC) Canada $2.824B 2.08
Amphastar Pharmaceuticals (AMPH) United States $2.031B 12.21
Taysha Gene Therapies (TSHA) United States $0.424B 29.57
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00